Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma
Monitoring malignant progression and disease recurrence post-therapy are central challenges to improving the outcomes of patients with multiple myeloma (MM). Whereas current detection methods that rely upon bone marrow examination allow for precise monitoring of minimal residual disease and can help...
Main Authors: | Nguyen, Hung V. -T., Johnson, Jeremiah A. |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Chemistry |
Format: | Article |
Language: | English |
Published: |
Royal Society of Chemistry (RSC)
2020
|
Online Access: | https://hdl.handle.net/1721.1/124848 |
Similar Items
-
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
by: Jakub Radocha, et al.
Published: (2021-03-01) -
Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
by: Lijie Xing, et al.
Published: (2023-04-01) -
Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
by: Christie P. M. Verkleij, et al.
Published: (2021-03-01) -
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
by: Benedetta Dalla Palma, et al.
Published: (2020-09-01) -
Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma
by: Fabiola De Luca, et al.
Published: (2023-02-01)